Evidence map›Paper›PMID 32755317›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2020

Pulmonary fibrosis: something old, something new…still waiting for a breakthrough.

Carol Feghali-Bostwick

Abstract readEditorialComment
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Targeting ATP12A, a Nongastric Proton Pump α Subunit, for Idiopathic Pulmonary Fibrosis Treatment.American journal of respiratory cell and molecular biology · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Carol Feghali-BostwickDepartment of Medicine, Medical University of South Carolina, Charleston, South Carolina.

Funding

Proteomics CoreP30DK123704 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Garth R Swanson · 2020 to 2026
$8.8M
Role of pericytes in scleroderma skin and lung fibrosisR01HL133751 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI FEGHALI-BOSTWICK, CAROL A., SCHNAPP, LYNN M · 2017 to 2020
$2.0M
Mechanism of Action of Anti-Fibrotic PeptideR01HL121262 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI FEGHALI-BOSTWICK, CAROL A. · 2017 to 2020
$1.5M
IGF-II regulates lung fibrosis in sclerodermaR01HL153195 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI FEGHALI-BOSTWICK, CAROL A. · 2020 to 2023
$1.5M
HHS | NIH | National Heart, Lung, and Blood Institute (NHBLI) 1R01HL121262HHS | NIH | National Heart, Lung, and Blood Institute (NHBLI) 1R01HL133751HHS | NIH | National Heart, Lung, and Blood Institute (NHBLI) 1R01HL153195NIDDK NIH HHS P30 DK123704
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Idiopathic Pulmonary FibrosisHumansfibrosisIPFlungpulmonary fibrosissystemic sclerosis

Identifiers

PMID32755317
PMCPMC7518060

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.